Calidi Biotherapeutics, Inc. has entered into an agreement to sell up to $5.1 million of its common stock through Ladenburg Thalmann & Co. Inc., with a commission of 3% on sales. The company is not obligated to sell any shares under this agreement, which can be terminated by either party.